Cellular therapy of systemic lupus erythematosus

Lupus

Volumn 18, Issue 5, 2009, Pages 387-393

  Tyndall, Alan ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Autoimmune disease; Lupus; MSC; Stem cell; Transplantation

Indexed keywords

CYCLOPHOSPHAMIDE; TUMOR NECROSIS FACTOR ALPHA;

ADJUVANT ARTHRITIS; ADULT STEM CELL; ALLERGIC ENCEPHALOMYELITIS; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOIMMUNE DISEASE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL THERAPY; DIABETES MELLITUS; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; MESENCHYMAL STEM CELL TRANSPLANTATION; MUCORMYCOSIS; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; STEM CELL MOBILIZATION; SYSTEMIC LUPUS ERYTHEMATOSUS;

CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; EVIDENCE-BASED DENTISTRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNE TOLERANCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MESENCHYMAL STEM CELL TRANSPLANTATION; REMISSION INDUCTION; TRANSPLANTATION CONDITIONING;

EID: 63749106135     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203308100385     Document Type: Article

References (33)

1. Robbins WC, Holman HR, Deicher H, Kunkel HG. Complement fixation with cell nuclei and DNA in lupus erythematosus. Proc Soc Exp Biol Med 1957; 96: 575-579.
2. van Laar JM, Tyndall A. Cellular therapy of systemic sclerosis. Curr Rheumatol Rep 2008; 10: 189-194.
3. Tamm M, Gratwohl A, Tichelli A, Perruchoud AP, Tyndall A. Autologous haemopoietic stem cell transplantation in a patient with severe pulmonary hypertension complicating connective tissue disease. Ann Rheum Dis 1996; 55: 779-780.
4. van Bekkum DW. Stem cell transplantation for autoimmune disorders. Preclinical experiments. Best Pract Res Clin Haematol 2004; 17: 201-222.
5. Smith-Berdan S, Gille D, Weissman IL, Christensen JL. Reversal of autoimmune disease in lupus-prone New Zealand black/New Zealand white mice by nonmyeloablative transplantation of purified allogeneic hematopoietic stem cells. Blood 2007; 110: 1370-1378.
6. van Laar JM, Tyndall A. Adult stem cells in the treatment of autoimmune diseases. Rheumatology (Oxford) 2006; 45: 1187-1193.
7. Muraro PA, Douek DC, Packer A, et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med 2005; 201: 805-816.
8. McKendry RJ, Huebsch L, Leclair B. Progression of rheumatoid arthritis following bone marrow transplantation. A case report with a 13-year followup. Arthritis Rheum 1996; 39: 1246-1253.
9. Lowenthal RM, Cohen ML, Atkinson K, Biggs JC. Apparent cure of rheumatoid arthritis by bone marrow transplantation. J Rheumatol 1993; 20: 137-140.
10. Burt RK, Traynor A, Statkute L, et al. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA 2006; 295: 527-535.
11. Jayne D, Passweg J, Marmont A, et al. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus 2004; 13: 168-176.
12. Lehnhardt FG, Scheid C, Holtik U, et al. Autologous blood stem cell transplantation in refractory systemic lupus erythematodes with recurrent longitudinal myelitis and cerebral infarction. Lupus 2006; 15: 240-243.
13. Marmont AM, Gualandi F, van Lint MT, Guastoni C, Bacigalupo A. Long term complete remission of severe nephrotic syndrome secondary to diffuse global (IV-G) lupus nephritis following autologous, haematopoietic peripheral stem (CD34+) cell transplantation. Lupus 2006; 15: 44-46.
14. Statkute L, Traynor A, Oyama Y, et al. Antiphospholipid syndrome in patients with systemic lupus erythematosus treated by autologous hematopoietic stem cell transplantation. Blood 2005; 106: 2700-2709.
15. Traynor AE, Corbridge TC, Eagan AE, et al. Prevalence and reversibility of pulmonary dysfunction in refractory systemic lupus: Improvement correlates with disease remission following hematopoietic stem cell transplantation. Chest 2005; 127: 1680-1689.
16. Leng XM, Zhao Y, Zhou DB, et al. A pilot trial for severe, refractory systemic autoimmune disease with stem cell transplantation. Chin Med Sci J 2005; 20: 159-165.
17. Javazon EH, Beggs KJ, Flake AW. Mesenchymal stem cells: Paradoxes of passaging. Exp Hematol 2004; 32: 414-425.
18. Dazzi F, van Laar JM, Cope A, Tyndall A. Cell therapy for autoimmune diseases. Arthritis Res Ther 2007; 9: 206-215.
19. Traggiai E, Volpi S, Schena F, et al. Bone marrow-derived mesenchymalstem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. Stem Cells 2008; 26: 562-569.
20. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363: 1439-1441.
21. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371: 1579-1586.
22. Bocelli-Tyndall C, Bracci L, Spagnoli G, et al. Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and autoimmune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro. Rheumatology (Oxford) 2007; 46: 403-408.
23. Larghero J, Farge D, Braccini A, et al. Phenotypical and functional characteristics of in vitro expanded bone marrow mesenchymal stem cells from patients with systemic sclerosis. Ann Rheum Dis 2008; 67: 443-449.
24. Thiel A, Alexander T, Schmidt CA, et al. Direct assessment of thymic reactivation after autologous stem cell transplantation. Acta Haematol 2008; 119: 22-27.
25. Radbruch A, Muehlinghaus G, Luger EO, et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 2006; 6: 741-750.
26. Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99: 3838-3843.
27. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004; 103: 4619-4621.
28. Zappia E, Casazza S, Pedemonte E, et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005; 106: 1755-1761.
29. Glennie S, Soeiro I,Dyson PJ, Lam EW, Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005; 105: 2821-2827.
30. Plumas J, Chaperot L, Richard MJ, Molens JP, Bensa JC, Favrot MC. Mesenchymal stem cells induce apoptosis of activated T cells. Leukemia 2005; 19: 1597-1604.
31. Sato K, Ozaki K, Oh I, et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007; 109: 228-234.
32. Ortiz LA, Dutreil M, Fattman C, et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci U S A 2007; 104: 11002-11007.
33. Nasef A, Mathieu N, Chapel A, et al. Immunosuppressive effects of mesenchymal stem cells: Involvement of HLA-G. Transplantation 2007; 84: 231-237.